Premium
Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer
Author(s) -
Caliskan M.,
Turkeri L.N.,
Mansuroglu B.,
Toktas G.,
Aksoy B.,
Unluer E.,
Akdas A.
Publication year - 1997
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1997.06911.x
Subject(s) - bladder cancer , mutant , p53 protein , oncology , cancer , medicine , cancer research , urology , biology , genetics , gene , immunohistochemistry
Objective To investigate the expression and importance of the nuclear accumulation of p53 in superficial transitional cell carcinoma (TCC) of the bladder and its role as a predictor of response to treatment. Patients and methods Tumour samples from 30 patients (two women and 28 men, mean age 60.1 years, range 44–75) with pTa/pT1 tumours were assessed immunohistochemically using the Pab1801 monoclonal antibody and standard avidin‐biotin peroxidase staining for p53 protein. Results Tumours from six patients (20%) showed nuclear accumulation of p53; five of these patients failed intravesical therapy with bacille Calmette‐Guèrin (BCG) and progressed to muscle invasive and/or metastatic disease, in contrast to six of 24 patients with no detectable nuclear oncoprotein. Conclusions The nuclear accumulation of p53 appears to be a prognostic indicator of tumour unresponsive to intravesical treatment, even with the most potent agent (BCG). Therefore, early radical treatment modalities must be seriously considered in this group of patients.